[{"id":"3272fb35-7910-45fd-a4ab-4ef1f176f237","acronym":"BGB-3111-218","url":"https://clinicaltrials.gov/study/NCT05068440","created_at":"2021-10-05T20:00:21.125Z","updated_at":"2025-02-25T12:38:01.088Z","phase":"Phase 2","brief_title":"Treatment of CD79B Mutant Relapsed/Refractory Diffuse Large B-Cell Lymphoma With Bruton Tyrosine Kinase Inhibitor Zanubrutinib","source_id_and_acronym":"NCT05068440 - BGB-3111-218","lead_sponsor":"BeiGene","biomarkers":" CD79B","pipe":" | ","alterations":" CD79B mutation • CD79B mutation","tags":["CD79B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD79B mutation • CD79B mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Brukinsa (zanubrutinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 66","initiation":"Initiation: 08/11/2021","start_date":" 08/11/2021","primary_txt":" Primary completion: 10/21/2025","primary_completion_date":" 10/21/2025","study_txt":" Completion: 10/21/2025","study_completion_date":" 10/21/2025","last_update_posted":"2025-02-24"},{"id":"a15f3c21-a490-40cc-93c8-4d2c83593905","acronym":"","url":"https://clinicaltrials.gov/study/NCT05290337","created_at":"2022-03-22T12:52:47.199Z","updated_at":"2024-07-02T16:36:15.000Z","phase":"Phase 2","brief_title":"ZR-CHOP in DLBCL With Specific Gene Abnormality","source_id_and_acronym":"NCT05290337","lead_sponsor":"Fudan University","biomarkers":" TP53 • MYC • MYD88 • CD79B","pipe":" | ","alterations":" TP53 mutation • NOTCH1 mutation • MYD88 mutation • CD79B mutation • CD79B mutation • MYC translocation","tags":["TP53 • MYC • MYD88 • CD79B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • NOTCH1 mutation • MYD88 mutation • CD79B mutation • CD79B mutation • MYC translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • Brukinsa (zanubrutinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 62","initiation":"Initiation: 01/04/2022","start_date":" 01/04/2022","primary_txt":" Primary completion: 01/04/2024","primary_completion_date":" 01/04/2024","study_txt":" Completion: 01/04/2026","study_completion_date":" 01/04/2026","last_update_posted":"2022-03-22"},{"id":"a86fead0-6d68-4e5e-8342-7224d15b5ca0","acronym":"","url":"https://clinicaltrials.gov/study/NCT04994626","created_at":"2021-08-06T12:53:05.326Z","updated_at":"2024-07-02T16:36:26.846Z","phase":"Phase 2","brief_title":"Ibrutinib Combined With Rituximab for Treatment of Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBCL Who Have Received at Least Two Prior Therapies","source_id_and_acronym":"NCT04994626","lead_sponsor":"Chinese Academy of Medical Sciences","biomarkers":" CD20 • MYD88 • CD79B • CD79A","pipe":" | ","alterations":" CD79B mutation • CD79A mutation • CD79A mutation + CD79B mutation","tags":["CD20 • MYD88 • CD79B • CD79A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD79B mutation • CD79A mutation • CD79A mutation + CD79B mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • Rituxan (rituximab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 10/01/2021","start_date":" 10/01/2021","primary_txt":" Primary completion: 04/01/2022","primary_completion_date":" 04/01/2022","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2021-08-06"},{"id":"006e2786-ec9f-435c-b1a8-55c1b4f1678e","acronym":"PROTEOM","url":"https://clinicaltrials.gov/study/NCT04183569","created_at":"2021-01-18T20:23:47.835Z","updated_at":"2024-07-02T16:36:45.526Z","phase":"","brief_title":"Identification Predictive Markers of Immunochemotherapy Response to the Primary Cutaneous Diffuse Large B Cell Lymphoma","source_id_and_acronym":"NCT04183569 - PROTEOM","lead_sponsor":"University Hospital, Bordeaux","biomarkers":" BCL2 • CDKN2A • MYD88 • CD79B • TNFAIP3 • PIM1 • PRDM1","pipe":" | ","alterations":" CDKN2A deletion • MYD88 mutation • CD79B mutation • PIM1 mutation","tags":["BCL2 • CDKN2A • MYD88 • CD79B • TNFAIP3 • PIM1 • PRDM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDKN2A deletion • MYD88 mutation • CD79B mutation • PIM1 mutation"],"overall_status":"Unknown status","enrollment":" Enrollment 32","initiation":"Initiation: 02/19/2019","start_date":" 02/19/2019","primary_txt":" Primary completion: 05/01/2020","primary_completion_date":" 05/01/2020","study_txt":" Completion: 05/01/2020","study_completion_date":" 05/01/2020","last_update_posted":"2020-04-29"}]